21440-97-1

Basic information

• Product Name: BROFOXINE
• Synonyms: 6-BROMO-4,4-DIMETHYL-1,4-DIHYDRO-BENZO[D][1,3]OXAZIN-2-ONE;BROFOXINE;1,2-dihydro-6-bromo-4,4-dimethyl-4h-1-benzoxazin-2-one;4h-4-dimethyl-6-bromo-3,1-benzoxazine-2-one;6-bromo-1,4-dihydro-4,4-dimethyl-2h-1-benzoxazin-2-one;6-bromo-1,4-dihydro-4,4-dimethyl-2h-3,1-benzoxazin-2-one;dimethabrone;Brofoxine-4,4-Dimethyl-6-Bromo-1,3-Benxoxazine-2-One(Or)
• CAS NO: 21440-97-1
• Molecular Formula: C₁₀H₁₀BrNO₂
• Molecular Weight: 256.1
• EINECS: 244-389-7
• Product Categories: Active Pharmaceutical Ingredients
• Mol File: 21440-97-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 269.8 °C at 760 mmHg
• Flash Point: 117 °C
• Appearance: /
• Density: 1.468 g/cm³
• Vapor Pressure: 0.00711mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BROFOXINE(CAS DataBase Reference)
• NIST Chemistry Reference: BROFOXINE(21440-97-1)
• EPA Substance Registry System: BROFOXINE(21440-97-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 21440-97-1(Hazardous Substances Data)

Usage

Uses

Antipsychotic.

InChI:InChI=1/C10H10BrNO2/c1-10(2)7-5-6(11)3-4-8(7)12-9(13)14-10/h3-5H,1-2H3,(H,12,13)

Upstream product

• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 75-16-1 methylmagnesium bromide 
• 21440-96-0 1,4-Dihydro-4,4-dimethyl-1,3-benzo[d]oxazin-2-one 
• 15833-00-8 o-aminophenyldimethylcarbinol 
• 551-93-9 2-aminoacetophenone 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 530-62-1 1,1'-carbonyldiimidazole 
• 304853-89-2 2-(2-amino-5-bromophenyl)-propan-2-ol 

Downstream Products

• 304853-90-5 (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid 
• 304854-26-0 6-(3-Fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d] [1,3]-oxazin-2-one 
• 304854-36-2 6-(3-Methoxy-phenyl)4,4-dimethyl-1,4-dihydro-benzo [d] [1,3]-oxazin-2one 
• 304853-28-9 6-(3-chlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazine-2-one 
• 305799-74-0 6-(4-Chloro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo [d] [1,3]-oxazin-2-one 
• 304854-37-3 6-(2-chloro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
• 304853-34-7 6-Bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-thione 
• 304854-45-3 6-(3-Chloro-4-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
• 304854-14-6 6-(3,5-dichloro-phenyl)-4,4-dimethyl-1,4-dihydrobenzo-[d][1,3]oxazin-2-one 
• 304854-07-7 5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3]oxazin-6-yl)-2-fluoro-benzonitrile 
• 304853-30-3 PRA-910 
• 304854-09-9 6-(3-Chloro-5-fluoro-phenyl)4,4-dimethyl-1,4-dihydro-benzo[d] [1,3]oxazin-2-one 
• 304853-36-9 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-3-yl)benzonitrile 

Relevant articles and documents

Acridine derivative heterocyclic aromatic compound and applicaiton of acridine derivative heterocyclic aromatic compound in organic electroluminescent component

The invention relates to an acridine derivative heterocyclic aromatic compound and applicaiton of the acridine derivative heterocyclic aromatic compound in an organic electroluminescent component. Theacridine derivative heterocyclic aromatic compound is represented by a general formula (1-1) or (1-2); through modification by increasing necessary electron-donating groups, hole transportability canbe improved, the triplet energy of the material can be improved, and high brightness, low voltage, high efficiency and long service life of the organic EL component can be achieved; meanwhile, the material prepared from the compound has high thermal stability, the luminescent stability of a light-emitting device can be improved significantly, and the material can be widely used as a host materialof a luminescent layer on the OLED and a display device.

SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR

Compounds of formula (I), or pharmaceutically acceptable salts thereof, are provided, wherein R1-R6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I), pharmaceutical compositions and kits containing a compound of formula (I), as are methods of treating endometriosis, hormone-dependent carcinomas, leiomyoma, fibroids, dysfunctional bleeding, polycystic ovary syndrome, and menopause related symptoms; methods of contraception; methods of providing hormone replacement therapy; methods of stimulating food intake; methods of synchronizing estrus; and methods of treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder by administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (I).

Synthesis and structure-activity relationship of novel 6-aryl-1,4- dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget

Tanaproget represents a potential first-in-class nonsteroidal PR agonist for contraception with improved safety and side effect profiles versus currently available steroidal oral contraceptives. Additional SAR, biological activity, and structural information from a tanaproget/hPR-LBD (hPR-LBD = human progesterone receptor ligand binding domain) cocrystal structure will also be presented.